ZNF224 and B-cell chronic lymphocytic leukemia: We provide the first indication that ZNF224 could be a new potential biomarker of disease progression and therapy responsiveness, based on the relationship between ZNF224 expression and known prognostic and predictive markers and the assessment of its levels in clinical-risk stratified CLL patients (Rai et al., 1975; Binet et al., 1981; National Comprehensive Cancer Network (NCCN), 2017) and in treated patients classified according to their treatment outcome.